BR112014008555A2 - r(+)-n-formil-propargil-aminoindano - Google Patents
r(+)-n-formil-propargil-aminoindanoInfo
- Publication number
- BR112014008555A2 BR112014008555A2 BR112014008555A BR112014008555A BR112014008555A2 BR 112014008555 A2 BR112014008555 A2 BR 112014008555A2 BR 112014008555 A BR112014008555 A BR 112014008555A BR 112014008555 A BR112014008555 A BR 112014008555A BR 112014008555 A2 BR112014008555 A2 BR 112014008555A2
- Authority
- BR
- Brazil
- Prior art keywords
- aminoindane
- propargyl
- formyl
- compound
- pharmaceutically acceptable
- Prior art date
Links
- XJEVHMGJSYVQBQ-SECBINFHSA-N (1r)-2,3-dihydro-1h-inden-1-amine Chemical compound C1=CC=C2[C@H](N)CCC2=C1 XJEVHMGJSYVQBQ-SECBINFHSA-N 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/02—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
- C07C233/03—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to hydrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Psychology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161545422P | 2011-10-10 | 2011-10-10 | |
| PCT/US2012/059356 WO2013055687A2 (en) | 2011-10-10 | 2012-10-09 | R(+)-n-formyl-propargyl-aminoindan |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112014008555A2 true BR112014008555A2 (pt) | 2017-04-18 |
Family
ID=48042235
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112014008555A BR112014008555A2 (pt) | 2011-10-10 | 2012-10-09 | r(+)-n-formil-propargil-aminoindano |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US9346746B2 (https=) |
| EP (1) | EP2766002A4 (https=) |
| JP (1) | JP2014534196A (https=) |
| KR (1) | KR20140090996A (https=) |
| CN (1) | CN103874487A (https=) |
| AR (1) | AR088297A1 (https=) |
| AU (1) | AU2012323349A1 (https=) |
| BR (1) | BR112014008555A2 (https=) |
| CA (1) | CA2851276A1 (https=) |
| EA (1) | EA201490761A1 (https=) |
| HK (1) | HK1200315A1 (https=) |
| IL (1) | IL231721A0 (https=) |
| MX (1) | MX2014004308A (https=) |
| WO (1) | WO2013055687A2 (https=) |
| ZA (1) | ZA201403043B (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2551481T3 (es) * | 2006-02-21 | 2015-11-19 | Teva Pharmaceutical Industries, Ltd. | Uso de rasagilina para el tratamiento de atrofia multisistémica |
| JP5769923B2 (ja) * | 2006-04-03 | 2015-08-26 | テバ ファーマシューティカル インダストリーズ リミティド | レストレスレッグス症候群の治療のためのラサギリンの使用 |
| CN101557706B (zh) * | 2006-12-14 | 2013-08-07 | 泰华制药工业有限公司 | 雷沙吉兰碱结晶固体 |
| EP2234478A4 (en) * | 2008-01-11 | 2013-01-23 | Teva Pharma | RASAGILINE FORMULATIONS, THEIR PREPARATION AND USE |
| WO2009151594A1 (en) * | 2008-06-10 | 2009-12-17 | Teva Pharmaceutical Industries, Ltd. | Rasagiline soft gelatin capsules |
| SI2451771T1 (sl) | 2009-07-09 | 2014-10-30 | Ratiopharm Gmbh | Soli rasagilina in njihovi farmacevtski pripravki |
| AU2010304755A1 (en) * | 2009-10-09 | 2012-05-24 | Teva Pharmaceutical Industries, Ltd. | Use of rasagiline for the treatment of Progressive Supranuclear Palsy |
| EP2515891A4 (en) * | 2009-12-22 | 2013-06-05 | Teva Pharma | 3-keto-N-propargyl-1-aminoindan |
| JP2013537530A (ja) | 2010-07-27 | 2013-10-03 | テバ ファーマシューティカル インダストリーズ リミティド | ラサギリンシトレートの分散物 |
| JP2014534197A (ja) | 2011-10-10 | 2014-12-18 | テバ ファーマシューティカル インダストリーズ リミティド | Ｒ（＋）−ｎ−メチル−プロパルギルアミノインダン |
| JP2015529196A (ja) | 2012-08-17 | 2015-10-05 | テバ ファーマシューティカル インダストリーズ リミティド | ラサギリンの非経口製剤 |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3201470A (en) * | 1965-08-17 | Chsx c cech | ||
| US5744500A (en) | 1990-01-03 | 1998-04-28 | Teva Pharmaceutical Industries, Ltd. | Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof |
| IL92952A (en) | 1990-01-03 | 1994-06-24 | Teva Pharma | R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them |
| IL99759A (en) | 1991-10-16 | 1997-06-10 | Teva Pharma | Mono-fluorinated derivatives of n-propargyl-1-aminoindan, their preparation and pharmaceutical compositions containing them |
| IL111240A (en) * | 1993-10-18 | 2001-10-31 | Teva Pharma | Salts of r(+) - enantiomers of n- propargyl-1-aminoindan and pharmaceutical compositions comprising them |
| US5877218A (en) * | 1994-01-10 | 1999-03-02 | Teva Pharmaceutical Industries, Ltd. | Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives |
| EP0738149B1 (en) * | 1994-01-10 | 2006-11-29 | Teva Pharmaceutical Industries, Ltd. | 1-aminoindan derivatives and compositions thereof |
| IL115357A (en) * | 1995-09-20 | 2000-01-31 | Teva Pharma | Stable compositions containing N-propargyl-1-aminoindan and polyhydric alcohols |
| IL118836A (en) | 1996-07-11 | 2001-01-11 | Teva Pharma | Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan |
| ES2241064T3 (es) | 1996-12-18 | 2005-10-16 | Teva Pharmaceutical Industries, Ltd. | Derivados de aminoindano. |
| JP2003512426A (ja) * | 1999-10-27 | 2003-04-02 | テバ ファーマシューティカル インダストリーズ リミティド | 双極性気分障害における躁病の治療のための１−アミノインダンの使用。 |
| ES2432117T3 (es) | 2002-11-15 | 2013-11-29 | Teva Pharmaceutical Industries Limited | Uso de rasagilina con riluzol para tratar la esclerosis lateral amiotrófica |
| WO2004072250A2 (en) | 2003-02-06 | 2004-08-26 | University Of Georgia Research Foundation, Inc. | Galacturonosyl transferases, nucleic acids encoding same and uses therefor |
| WO2006014973A2 (en) | 2004-07-26 | 2006-02-09 | Teva Pharmaceutical Industries, Ltd. | Pharmaceutical dosage forms including rasagiline |
| US20090111892A1 (en) | 2004-11-24 | 2009-04-30 | Shulamit Patashnik | Rasagiline Orally Disintegrating Compositions |
| WO2006091657A1 (en) | 2005-02-23 | 2006-08-31 | Teva Pharmaceutical Industries, Ltd. | Rasagiline formulations of improved content uniformity |
| CA2630037C (en) | 2005-11-17 | 2015-03-31 | Teva Pharmaceutical Industries Ltd. | Methods for isolating propargylated aminoindans |
| US7572834B1 (en) | 2005-12-06 | 2009-08-11 | Teva Pharmaceutical Industries, Ltd. | Rasagiline formulations and processes for their preparation |
| ES2551481T3 (es) | 2006-02-21 | 2015-11-19 | Teva Pharmaceutical Industries, Ltd. | Uso de rasagilina para el tratamiento de atrofia multisistémica |
| JP5769923B2 (ja) | 2006-04-03 | 2015-08-26 | テバ ファーマシューティカル インダストリーズ リミティド | レストレスレッグス症候群の治療のためのラサギリンの使用 |
| EP1892233A1 (de) | 2006-08-18 | 2008-02-27 | Ratiopharm GmbH | Neue Salze des Wirkstoffs Rasagilin |
| CN101557706B (zh) | 2006-12-14 | 2013-08-07 | 泰华制药工业有限公司 | 雷沙吉兰碱结晶固体 |
| CN101600346B (zh) | 2006-12-14 | 2013-08-21 | 泰华制药工业有限公司 | 雷沙吉兰的单宁酸盐 |
| EP1987816A1 (de) | 2007-04-30 | 2008-11-05 | Ratiopharm GmbH | Adsorbate eines Rasagilinsalzes mit einem wasserlöslichen Hilfsstoff |
| CA2698695A1 (en) | 2007-09-05 | 2009-03-12 | Teva Pharmaceutical Industries Ltd. | Method of treating glaucoma using rasagiline |
| US8188149B2 (en) | 2007-09-17 | 2012-05-29 | Teva Pharmaceutical Industries, Ltd. | Use of R(+)-N-propargy1-1-aminoindan to treat or prevent hearing loss |
| EP2234478A4 (en) | 2008-01-11 | 2013-01-23 | Teva Pharma | RASAGILINE FORMULATIONS, THEIR PREPARATION AND USE |
| WO2009151594A1 (en) | 2008-06-10 | 2009-12-17 | Teva Pharmaceutical Industries, Ltd. | Rasagiline soft gelatin capsules |
| MX2010013766A (es) | 2008-06-13 | 2011-03-15 | Teva Pharmaceutical Ind Ltd Star | Rasagilina para modificacion de enfermedad de parkinson. |
| BRPI0909997A2 (pt) | 2008-06-19 | 2015-10-27 | Teva Pharma | r(+)-n-propargil-1-aminoindano cristalino, composição farmacêutica, processo de secagem de r(+)-n-propargil-1-aminoindano sólido, processo de preparação de uma composição farmacêutica, processo de produção de um lote validado de um produto de farmaco que contém r(+)-n-propargil-1-aminoindano cristalino e pelo menos um veículo farmaceuticamente aceitável para distribuição e processo de prudução de r(+)-n-propargil-1-aminoindano cristalino |
| US8334409B2 (en) | 2008-06-19 | 2012-12-18 | Teva Pharmaceutical Industries, Ltd. | Process for purifying rasagiline base |
| DE102008064061A1 (de) | 2008-12-19 | 2010-06-24 | Ratiopharm Gmbh | Feste Zusammensetzung mit dem Wirkstoff Rasagilin |
| US20100189791A1 (en) | 2009-01-23 | 2010-07-29 | Teva Pharmaceutical Industries, Ltd. | Delayed release rasagiline malate formulation |
| SI2451771T1 (sl) | 2009-07-09 | 2014-10-30 | Ratiopharm Gmbh | Soli rasagilina in njihovi farmacevtski pripravki |
| AU2010304755A1 (en) | 2009-10-09 | 2012-05-24 | Teva Pharmaceutical Industries, Ltd. | Use of rasagiline for the treatment of Progressive Supranuclear Palsy |
| CN102048717B (zh) * | 2009-10-29 | 2014-02-19 | 重庆医药工业研究院有限责任公司 | 一种稳定的雷沙吉兰组合物 |
| EP2515891A4 (en) * | 2009-12-22 | 2013-06-05 | Teva Pharma | 3-keto-N-propargyl-1-aminoindan |
| AU2011282720B2 (en) | 2010-07-27 | 2016-12-22 | Teva Pharmaceutical Industries Ltd. | Use of rasagiline for the treatment of olfactory dysfunction |
| JP2013537530A (ja) | 2010-07-27 | 2013-10-03 | テバ ファーマシューティカル インダストリーズ リミティド | ラサギリンシトレートの分散物 |
| SG189454A1 (en) | 2010-10-26 | 2013-05-31 | Teva Pharma | Deuterium enriched rasagiline |
| AU2012323346A1 (en) | 2011-10-10 | 2014-05-15 | Teva Pharmaceutical Industries Ltd | Rasagiline citramide |
| JP2014534197A (ja) | 2011-10-10 | 2014-12-18 | テバ ファーマシューティカル インダストリーズ リミティド | Ｒ（＋）−ｎ−メチル−プロパルギルアミノインダン |
| JP2015529196A (ja) | 2012-08-17 | 2015-10-05 | テバ ファーマシューティカル インダストリーズ リミティド | ラサギリンの非経口製剤 |
-
2012
- 2012-10-09 HK HK15100235.8A patent/HK1200315A1/xx unknown
- 2012-10-09 US US13/647,685 patent/US9346746B2/en not_active Expired - Fee Related
- 2012-10-09 BR BR112014008555A patent/BR112014008555A2/pt not_active IP Right Cessation
- 2012-10-09 EP EP12839776.7A patent/EP2766002A4/en not_active Withdrawn
- 2012-10-09 MX MX2014004308A patent/MX2014004308A/es unknown
- 2012-10-09 AU AU2012323349A patent/AU2012323349A1/en not_active Abandoned
- 2012-10-09 KR KR1020147012454A patent/KR20140090996A/ko not_active Withdrawn
- 2012-10-09 EA EA201490761A patent/EA201490761A1/ru unknown
- 2012-10-09 CA CA2851276A patent/CA2851276A1/en not_active Abandoned
- 2012-10-09 JP JP2014535789A patent/JP2014534196A/ja active Pending
- 2012-10-09 WO PCT/US2012/059356 patent/WO2013055687A2/en not_active Ceased
- 2012-10-09 CN CN201280049741.8A patent/CN103874487A/zh active Pending
- 2012-10-10 AR ARP120103781A patent/AR088297A1/es unknown
-
2014
- 2014-03-26 IL IL231721A patent/IL231721A0/en unknown
- 2014-04-25 ZA ZA2014/03043A patent/ZA201403043B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2012323349A1 (en) | 2014-05-22 |
| WO2013055687A3 (en) | 2013-07-25 |
| NZ624206A (en) | 2016-11-25 |
| AR088297A1 (es) | 2014-05-21 |
| JP2014534196A (ja) | 2014-12-18 |
| IL231721A0 (en) | 2014-05-28 |
| EP2766002A2 (en) | 2014-08-20 |
| EP2766002A4 (en) | 2015-07-01 |
| ZA201403043B (en) | 2015-08-26 |
| CN103874487A (zh) | 2014-06-18 |
| EA201490761A1 (ru) | 2014-11-28 |
| HK1200315A1 (en) | 2015-08-07 |
| MX2014004308A (es) | 2014-07-24 |
| KR20140090996A (ko) | 2014-07-18 |
| US20130089612A1 (en) | 2013-04-11 |
| WO2013055687A2 (en) | 2013-04-18 |
| CA2851276A1 (en) | 2013-04-18 |
| US9346746B2 (en) | 2016-05-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112014008555A2 (pt) | r(+)-n-formil-propargil-aminoindano | |
| MY163083A (en) | Solid forms of a pharmaceutically active substance | |
| CR20150078A (es) | Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn | |
| BR112013006769A2 (pt) | combinação sinérgica de um anticorpo específico para cd38 | |
| PH12015502031B1 (en) | Tetrahydropyrrolothiazine compounds | |
| IN2014DN10670A (https=) | ||
| BR112016011755A2 (pt) | derivado de ureia ou sal farmacologicamente aceitável do mesmo | |
| PH12015500064A1 (en) | Imidazotriazinecarbonitriles useful as kinase inhibitors | |
| CR20140229A (es) | Nuevos derivados bicíclicos de dihidroisoquinolin-1-ona | |
| IN2014CN03506A (https=) | ||
| EA201391033A1 (ru) | Ингибиторы bace-2 для лечения метаболических расстройств | |
| BR112014019171A8 (pt) | Composições intranasais de dexdetomida e seus métodos de uso | |
| MX391043B (es) | Formulaciones de anticuerpo y metodos. | |
| ECSP14013179A (es) | Compuesto inhibidor de la señalización de la trayectoria notch | |
| CR20130539A (es) | Triazolopiridinas | |
| MX2011007763A (es) | Metodos y composiciones para tratamiento de cancer de pulmon. | |
| BR112014025041B8 (pt) | Composição farmacêutica | |
| MX362879B (es) | Usos novedosos. | |
| BR112015006868A2 (pt) | composições antibióticas de tazobactam arginina | |
| EA201390616A1 (ru) | ЛЕЧЕНИЕ НАРУШЕНИЙ, АССОЦИИРОВАННЫХ С ГЕНОМ MeCP2 | |
| IN2014DN07996A (https=) | ||
| MX2015016332A (es) | Inhibidores de alk biciclicos fusionados. | |
| MX337612B (es) | Composicion de oligosacaridos para prevenir o reducir el riesgo de sindrome metabolico. | |
| BR112012026542A2 (pt) | abordagem seletiva de tecido | |
| BR112014009760A8 (pt) | análogos de ácido siálico |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2483 DE 07-08-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |